Skip to main content
Supplement Research and Comparison WebsiteBest Price Guarantee
Supplement Research and Comparison Website

Bifidobacterium breve prevents necrotising enterocolitis by suppressing inflammatory responses in a preterm rat model.

  • 2016-02-01
  • Beneficial Microbes 7(1)
    • T. Satoh
    • H. Izumi
    • N. Iwabuchi
    • T. Odamaki
    • K. Namba
    • F. Abe
    • J. Xiao

Abstract

Necrotising enterocolitis (NEC) is associated with inflammatory responses and barrier dysfunction in the gut. In this study, we investigated the effect of Bifidobacterium breve M-16V on factors related to NEC development using an experimental rat model. Caesarean-sectioned rats were given formula milk with or without B. breve M-16V by oral gavage thrice daily, and experimental NEC was induced by exposing the rats to hypoxic conditions. Naturally delivered rats that were reared by their mother were used as healthy controls. The pathological score of NEC and the expression of molecules related to inflammatory responses and the barrier function were assessed in the ileum. B. breve M-16V reduced the pathological scores of NEC and resulted in some improvement in survivability. B. breve M-16V suppressed the increased expression of molecules related to inflammation and barrier function that resulted from NEC induction. B. breve M-16V normalised Toll-like receptor (TRL)4 expression and enhanced TLR2 expression. Our data suggest that B. breve M-16V prevents NEC development by modulating TLR expressions and suppressing inflammatory responses in a rat model.

Keywords: Bifidobacterium; Toll-like receptors; necrotising enterocolitis.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Bifidobacterium breve M-16VReduced Inflammatory MoleculesBeneficial
Moderate
Bifidobacterium breve M-16VReduced Pathological SymptomsBeneficial
Moderate
Back to top